Integrating Microflow NMR into Fragment-based Drug Discovery

1. Integrating Microflow NMR into Fragment-based Drug Discovery

2. Integrating Microflow NMR into Fragment-based Drug Discovery Research Focus: Drug discovery using NMR Background on Fragment-based Drug Discovery NMR Equipment in the CPFM Flow Probe Applications Routine quality control of compound collections Protein 1H-15N HSQC screening of labeled proteins Fragment-based screening using STD (saturation transfer difference) NMR

3. New Drug Design Paradigm: Fragment-Assembly San Diego, California Initially funded June, 1999 Raised $42.5 M in A and B rounds; $15 M in C round 50+ employees

7. Triad Technology Platform � Internal use only Proprietary NMR-based drug design platform to generate drug leads Chemicals, proteins, software, databases, methods Proof of Principle completed (Series B, $30M) Leads for infectious disease targets Dual Business Strategy (Drug Discovery) Internal drug discovery & licensing early-stage leads Evolved into late-stage licensing (IND candidates) Triad ceased operations on 3/19/04: Drug licensing business model not practical

8. Drug Discovery in Academics Can focus on developing enabling methods rather than drug leads. The longer view � Focus on diseases with smaller markets; third world diseases. The CPFM has resources to aid in drug discovery: compounds; databases; software; NMR screening capability � automation & labeled probes.

11. NMR-based Drug Discoveryat Marquette�s CPFM Focus on developing new methods Blending: chemistry, NMR screening, informatics Integrating use of microflow NMR Focus on infectious disease

13. STD-based screening(STD = saturation transfer difference)

14. STD-based screening(STD = saturation transfer difference)

32. Acknowledgements